title: Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.
abstract: Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis. This failure underscores the need for better prognostic markers. Although many markers have been explored, this review focuses on the newer and most clinically relevant markers: cytogenetic aberrations, zeta-associated protein 70, immunoglobulin mutational status, and CD38 expression. Although these markers have been shown to predict outcomes for groups of patients, individual patients may have a variable course; therefore, the outcome for any one patient remains hard to predict. To date, no study has shown a benefit from early cytotoxic therapy for any subgroup of patients with chronic lymphocytic leukemia.
authors.affiliation: Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
authors.forename: Nitin
authors.initials: N
authors.lastname: Jain
authors.forename: Nicole
authors.initials: N
authors.lastname: Lamanna
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D002869:Chromosome Aberrations; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D011379:Prognosis; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region; D051746:ZAP-70 Protein-Tyrosine Kinase; D051997:ADP-ribosyl Cyclase 1
references.citation: Proc Natl Acad Sci U S A. 1989 Aug;86(15):5913-7
references.pmid: 2503826
references.citation: N Engl J Med. 2000 Dec 28;343(26):1910-6
references.pmid: 11136261
references.citation: Immunol Today. 1994 Jun;15(6):288-94
references.pmid: 7520700
references.citation: Br J Haematol. 1996 Feb;92(2):382-8
references.pmid: 8603004
references.citation: Blood. 2002 Feb 1;99(3):1023-9
references.pmid: 11807008
references.citation: Blood. 2002 Aug 15;100(4):1410-6
references.pmid: 12149225
references.citation: Blood. 2009 Apr 2;113(14):3168-71
references.pmid: 19050308
references.citation: J Clin Oncol. 2009 Feb 1;27(4):491-7
references.pmid: 19075280
references.citation: Blood. 2005 Nov 1;106(9):3175-82
references.pmid: 16014569
references.citation: Blood. 1997 Apr 1;89(7):2516-22
references.pmid: 9116297
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5616-23
references.pmid: 17984186
references.citation: Ann Hematol. 2003 Dec;82(12):759-65
references.pmid: 14551737
references.citation: Blood. 1999 Sep 15;94(6):1840-7
references.pmid: 10477712
references.citation: Blood. 1997 Jun 1;89(11):4153-60
references.pmid: 9166858
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4634-41
references.pmid: 17008705
references.citation: J Clin Oncol. 2007 Mar 1;25(7):799-804
references.pmid: 17283363
references.citation: Blood. 2001 Nov 1;98(9):2633-9
references.pmid: 11675331
references.citation: Blood. 1975 Aug;46(2):219-34
references.pmid: 1139039
references.citation: Blood. 2003 Jun 15;101(12):4944-51
references.pmid: 12595313
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3928-32
references.pmid: 14581416
references.citation: Blood. 1995 Mar 15;85(6):1580-9
references.pmid: 7888675
references.citation: J Clin Oncol. 2006 Jan 20;24(3):437-43
references.pmid: 16344317
references.citation: Blood. 2008 Sep 1;112(5):1923-30
references.pmid: 18577710
references.citation: Leukemia. 2005 May;19(5):750-8
references.pmid: 15759031
references.citation: Cancer. 2009 Jan 15;115(2):373-80
references.pmid: 19117034
references.citation: Blood. 2001 Mar 15;97(6):1902-3
references.pmid: 11263445
references.citation: Leukemia. 2004 Mar;18(3):476-83
references.pmid: 14712287
references.citation: Blood. 1993 Dec 1;82(11):3452-9
references.pmid: 8241511
references.citation: Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68
references.pmid: 17707833
references.citation: Leukemia. 1997 Nov;11(11):1929-32
references.pmid: 9369428
references.citation: Cancer. 1977 Aug;40(2):855-64
references.pmid: 890666
references.citation: Am J Hematol. 1998 Nov;59(3):223-9
references.pmid: 9798660
references.citation: Br J Haematol. 1990 Nov;76(3):352-8
references.pmid: 2261345
references.citation: Blood. 2003 Mar 1;101(5):2049-53
references.pmid: 12411304
references.citation: N Engl J Med. 2003 May 1;348(18):1764-75
references.pmid: 12724482
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):995-1004
references.pmid: 19188171
references.citation: Lancet. 2007 Jul 21;370(9583):230-239
references.pmid: 17658394
references.citation: Blood. 2001 Jul 1;98(1):181-6
references.pmid: 11418478
references.citation: N Engl J Med. 2004 Aug 26;351(9):893-901
references.pmid: 15329427
references.citation: Blood. 2008 Aug 15;112(4):975-80
references.pmid: 18411418
references.citation: Leukemia. 1995 Dec;9(12):2003-8
references.pmid: 8609709
references.citation: Blood. 2008 Oct 15;112(8):3322-9
references.pmid: 18689542
references.citation: Leuk Lymphoma. 2007 Feb;48(2):311-20
references.pmid: 17325891
references.citation: Blood. 1999 Sep 15;94(6):1848-54
references.pmid: 10477713
references.citation: Blood. 2004 May 1;103(9):3278-81
references.pmid: 14726385
references.citation: N Engl J Med. 2002 Aug 8;347(6):452-3
references.pmid: 12167696